Clinical Trial

13C-Glucose Tracing of Tumour and T Cells in the Ascites of Ovarian Cancer Patients.

Study acronym: iMETABO
Recruiting
View on ClinicalTrials.gov →
Summary
The objective of the study is to investigate the metabolism of cells in the ascites tumour microenvironment of ovarian cancer patients. This observational study involves intravenous infusion of \[U-13C\]glucose into patients during standard paracentesis.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-08-24; most recent amendment 2024-08-08.
Status change: Not Yet Recruiting → Recruiting 2021-10-25
Trial Details
NCT Number NCT05025878
Lead Sponsor British Columbia Cancer Agency
Collaborators: University of Texas Southwestern Medical Center, Van Andel Research Institute, University of Victoria
Conditions Ovarian Cancer, Ascites
Enrollment 10 participants
Start Date 2021-10-20
Primary Completion 2024-08 (estimated)
Study Completion 2024-08 (estimated)
Updated on ClinicalTrials.gov 2024-08-09